Medicine fusion specifically bound with human angiopoietin-2

An angiogenin and fusion technology, applied in the field of genetic engineering, can solve the problems of small molecular weight of small peptides

Inactive Publication Date: 2013-03-06
HAISCO PHARMA GRP INC
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] found that a class of small peptides can significantly inhibit the activity of angiopoietin (CN 200910159451.9, which is incorporated here for reference), but the molecular weight of such small peptides is small (approximately 1000-2000 Daltons), it is easily cleared by the kidneys in the human body, and cannot exert its effective activity in the body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine fusion specifically bound with human angiopoietin-2
  • Medicine fusion specifically bound with human angiopoietin-2
  • Medicine fusion specifically bound with human angiopoietin-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] This example describes the preparation of the X fragment sequence as:

[0082] QEECEWDPWTCEHM (SEQ ID NO: 1),

[0083] The sequence of X' fragments is:

[0084] MHECTWPDWECEEQ (SEQ ID NO:3)

[0085] Y is GGGKGGG (SEQ ID NO: 2)

[0086] Z is a monomethoxypolyethylene glycol with a molecular weight of 20,000 Daltons and activated by maleic imide at the end

[0087] a and b do not exist, that is, the number of amino acid residues is 0

[0088] n=2

[0089] The preparation method of the drug fusion body, the fusion body is named HSK-B-06 in the present invention.

[0090] HSK-B-06 plasmid clone

[0091] Cloning of plasmids expressing the following protein sequences:

[0092] QEECEWDPWTCEHMQEECEWDPWTCEHMGGGKGGGMHECTWPDWECEEQ MHECTWPDWECEEQ (SEQ ID NO: 4)

[0093] Primer 5' CATGCCATGGCC CAT ATG AAA TAC-3' (SEQ ID NO: 5)

[0094] 5'-CCGAATTCTCATTACTGTTCTTCGC-3' (SEQ ID NO:6)

[0095] The DNA sequence encoding the above protein sequence is as follows:

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicine fusion specifically bound with human angiopoietin-2, and also discloses a preparation method of the medicine fusion and a method for treating senile maculopathy, tumors, inflammatory diseases and endometriosis by using the medicine fusion.

Description

technical field [0001] The invention belongs to the field of genetic engineering, and relates to a specific drug fusion body combined with human angiopoietin-2 and its application. It mainly involves the use of genetic engineering methods to convert active polypeptide fragments (X) that can bind to human angiopoietin-2 n By connecting the chain with the (X) n Polypeptide fragment (X') composed of mirror image amino acid sequence n Linked together, with any modification of polymer, fatty acid and sugar modification at the linking chain. The formed drug fusion contains 2 segments of inverted repeat polypeptide fragment sequences (X) n with (X') n . The present invention also covers the application of the polypeptide and its modified products in treating diseases accompanied by abnormal proliferation of blood vessels. Background technique [0002] Many diseases are associated with abnormal angiogenesis, such as age-related macular degeneration, tumors and inflammatory dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K38/18A61P15/00A61P29/00A61P27/02A61P35/00
Inventor 于鹏展
Owner HAISCO PHARMA GRP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap